Cite
Mehta DA, Cohen E, Charafeddine M, et al. Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther. 2017;6(4):515-529doi: 10.1007/s40121-017-0171-0.
Mehta, D. A., Cohen, E., Charafeddine, M., Cohen, D. E., Bao, Y., Sanchez Gonzalez, Y., & Tran, T. T. (2017). Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infectious diseases and therapy, 6(4), 515-529. https://doi.org/10.1007/s40121-017-0171-0
Mehta, Darshan A, et al. "Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials." Infectious diseases and therapy vol. 6,4 (2017): 515-529. doi: https://doi.org/10.1007/s40121-017-0171-0
Mehta DA, Cohen E, Charafeddine M, Cohen DE, Bao Y, Sanchez Gonzalez Y, Tran TT. Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther. 2017 Dec;6(4):515-529. doi: 10.1007/s40121-017-0171-0. Epub 2017 Sep 22. PMID: 28939957; PMCID: PMC5700891.
Copy
Download .nbib